PISCATAWAY, N.J., Aug. 8, 2011 /PRNewswire/ — INNOPHARMA LLC announced today FDA
approval of its Abbreviated New Drug Application (ANDA) for
levetiracetam injection (the generic equivalent of Keppra® injection
from UCB Inc).
As the developer of this generic injectable drug, INNOPHARMA entered
into a license agreement with X-GEN Pharmaceuticals, Inc. for marketing
and product distribution in the US.
About INNOPHARMA:
INNOPHARMA is a sterile product development company, focused on
developing niche generic and specialty pharmaceutical products. Through
a business model of internal product development and commercialization
licensure, INNOPHARMA has a comprehensive infrastructure for development
of injectable and ophthalmic pharmaceutical products at its New Jersey
facilities. INNOPHARMA works with manufacturing and clinical research
organizations worldwide for commercialization of its developed products.
More information about INNOPHARMA can be found at www.innopharmallc.com.
About X-GEN:
X-GEN Pharmaceuticals, Inc. is focused on the development,
manufacture and delivery of specialty pharmaceutical products which
serve the healthcare community as effective, generic treatment choices.
X-GEN’s expanding product line offers a broad range of dosage forms
including injectables, anti-infective solutions, oral solids, and
inhalants. For more information about X-GEN Pharmaceuticals, Inc. call
(866) 390-4411, or visit the web-site at www.x-gen.us.
Source: INNOPHARMA LLC
